Cybin to Join Canaccord Genuity 44th Annual Growth Conference

Cybin Inc., a clinical-stage neuropsychiatry company, is dedicated to transforming mental healthcare through the development of innovative treatment options. Doug Drysdale, Cybin’s Chief Executive Officer, is set to participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13-14, 2024, in Boston, MA. 

Cybin is focused on creating next-generation therapeutics to meet the substantial unmet need for new treatments for mental health conditions. The company's mission is supported by a robust network of leading partners and internationally recognized scientists. These collaborations aim to advance Cybin’s proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens.

Currently, Cybin is developing CYB003, a deuterated psilocybin analog designed to treat major depressive disorder. Additionally, the company is working on CYB004, a deuterated DMT molecule intended for the treatment of generalized anxiety disorder. Both of these proprietary compounds are part of Cybin’s extensive research pipeline focused on investigational psychedelic-based treatments.

Founded in 2019 and headquartered in Canada, Cybin operates in multiple countries including the United States, the United Kingdom, the Netherlands, and Ireland. The company remains committed to providing updates and information about its progress and initiatives through its website and various social media platforms such as X, LinkedIn, YouTube, and Instagram.

Cybin’s innovative approach and commitment to improving mental health treatment options underline its significant role in the field of neuropsychiatry. By advancing new therapeutic solutions, Cybin aims to address the critical need for effective treatments for individuals suffering from mental health conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!